Sign Out
Postmenopausal osteoporosis: Prolia is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. In postmenopausal women with osteoporosis, Prolia increases bone mineral density (BMD) and reduces the incidence of hip, vertebral and non-vertebral fractures.
Bone loss in patients undergoing hormone ablation for cancer: Prolia is indicated for the treatment of bone loss in patients undergoing hormone ablation for prostate or aromatase inhibitor treatment for breast cancer. In patients with prostate cancer, Prolia reduces the incidence of vertebral fractures.
Male osteoporosis: Prolia is indicated as a treatment to increase bone mass in men with osteoporosis at increased risk of fracture.
Glucocorticoid-induced osteoporosis: Treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
Continue with Google